



SDI Review Form 1.6

Journal Name:	<u>Journal of Cancer and Tumor International</u>
Manuscript Number:	Ms_JCTI_31424
Title of the Manuscript:	Case Report of Prolonged Stable Disease with Modified Schedule Sunitinib in Metastatic Renal Cell Carcinoma
Type of the Article	Case Report

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The authors present an interesting case report showing a complete remission of a patient with kidney tumor and lung metastases, who underwent nephrectomy and was treated with sunitinib. As stated in the discussion, complete remission occurs after treatment with tyrosine kinase inhibitors in less than 3% of patients. It is missing, the initial PET, showing renal tumor and pulmonary metastases. Tumor staging should be described as well as Fuhrman's degree. It is missing, the initial PET, showing renal tumor and pulmonary metastases. Tumor staging should be described as well as Fuhrman's degree.	The patient no longer has his old histopathology report which could give us the information regarding the tumor staging. We have now included the initial CT-scan image showing the renal tumor along with pulmonary metastasis. (Figure -1).
Minor REVISION comments		